Cart
sales@molnova.com
Minodronic acid monohydrate
CAS No. 155648-60-5
Minodronic acid monohydrate( —— )
Catalog No. M21947 CAS No. 155648-60-5
Minodronic acid monohydrate is an farnesyl diphosphate synthase inhibitor that acts as a bone resorption inhibitor.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 10MG | 38 | In Stock |
|
| 25MG | 67 | In Stock |
|
| 50MG | 91 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameMinodronic acid monohydrate
-
NoteResearch use only, not for human use.
-
Brief DescriptionMinodronic acid monohydrate is an farnesyl diphosphate synthase inhibitor that acts as a bone resorption inhibitor.
-
DescriptionMinodronic acid monohydrate is an farnesyl diphosphate synthase inhibitor that acts as a bone resorption inhibitor.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayMetabolic Enzyme/Protease
-
TargetTransferase
-
RecptorFarnesyl diphosphate synthase
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number155648-60-5
-
Formula Weight340.16
-
Molecular FormulaC9H14N2O8P2
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESO.OC(Cc1cnc2ccccn12)(P(O)(O)=O)P(O)(O)=O
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Airoldi A , Bettoni P , Donnola M , et al. Crystal structure of zwitterionic 3-(2-hydroxy-2-phosphonato-2-phosphonoethyl)imidazo[1, 2-a]-pyridin-1-ium monohydrate (minodronic acid monohydrate): A redetermination[J]. Acta Crystallogr E Crystallogr Commun, 2015.
molnova catalog
related products
-
GPAT-IN-1
GPAT-IN-1 is a glycerol 3-phosphate acyltransferase (GPAT) inhibitor, which can be used to study obesity and diabetes.
-
CBHcy
CBHcy is a dual-substrate analogue, a specific BHMT inhibitor that causes betaine-homocysteine S-methyltransferase (BHMT) to adopt the same conformation as the ternary complex, potentially inducing the development of cysteinemia.
-
FK866
FK866 (APO866, Daporinad) effectively inhibits nicotinamide phosphoribosyltransferase (NMPRTase) with IC50 of 0.09 nM in a cell-free assay. Phase 1/2.
